Good News for Novartis' Ilaris - Analyst Blog


Novartis ( NVS ) recently announced that the US Food and Drug Administration (FDA) has approved Ilaris (canakinumab) for an additional indication.

Ilaris is now approved for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients AGED 2 years and above in the US.

The approval was based on encouraging data from two phase III trials in SJIA patients (2 to 19 years) wherein a majority of Ilaris-treated patients showed considerable improvement. 

SJIA is the most severe type of juvenile idiopathic arthritis (JIA). We note that Ilaris is already approved in the US for the treatment of cryopyrin-associated periodic syndromes (CAPS).

Additionally, Novartis had filed for regulatory approval of Ilaris in the EU and the US in 2011 for the treatment of patients suffering from acute attacks of gout based on positive data from two phase III registration studies. In Mar 2013, Ilaris was approved by the EU for treating patients with acute gouty arthritis who suffer frequent attacks and their symptoms cannot be managed by the available treatment options.

However, the FDA approval is still pending for this indication. In Aug 2011, Novartis received a Complete Response Letter (CRL) from the US Food and Drug Administration asking for additional information to evaluate the risk benefit profile in refractory gout patients. Novartis continues to work with the FDA to determine the next steps for llaris in the gout indication.

Meanwhile, Ilaris is also being studied for a number of rare autoinflammatory conditions, including tumor necrosis factor receptor-associated periodic syndrome, colchicine-resistant familial mediterranean fever) and hyper IgD syndrome.

Ilaris generated sales of $24 million in the first quarter of 2013, up 54% year over year. The FDA approval for SJIA should boost sales further in our view.

Novartis currently carries a Zacks Rank #3 (Hold). Right now, Santarus Inc. ( SNTS ), Jazz Pharmaceuticals ( JAZZ ) and Salix Pharmaceuticals ( SLXP ) look attractive. All three carry a Zacks Rank #1(Strong Buy).

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

SANTARUS INC (SNTS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: CAPS , CRL , JAZZ , NVS , SLXP

More from

Related Videos




Most Active by Volume

  • $15.31 ▼ 0.71%
  • $32 ▲ 6.38%
  • $15.98 ▼ 0.19%
  • $8.57 ▲ 4.51%
  • $123.25 ▼ 0.80%
  • $40.97 ▼ 0.58%
  • $105.52 ▲ 0.40%
  • $5.67 ▼ 4.55%
As of 3/27/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by